Trials / Completed
CompletedNCT03825744
Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 15 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, placebo-control, phase III study to investigate hetrombopag in subjects with severe AA who are treated naive. 180 treated naive patients with SAA will be enrolled in the study. The primary objective of the study will be the rate of complete hematologic response at six months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hetrombopag Olamine+Standard Therapy | once daily |
| DRUG | Placebo+Standard Therapy | once daily |
Timeline
- Start date
- 2019-03-05
- Primary completion
- 2024-07-03
- Completion
- 2024-07-03
- First posted
- 2019-01-31
- Last updated
- 2024-11-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03825744. Inclusion in this directory is not an endorsement.